Can Lupin Sustain Its Margin Expansion and Global Growth?

Lupin Q2 FY26 results underline strong growth in the US and Emerging Markets with margins expanding well above expectations.

Can Lupin Sustain Its Margin Expansion and Global Growth Momentum?

About Lupin

Lupin is among India’s top pharmaceutical companies with strong presence across generics, branded formulations, and specialty products. It continues to strengthen US, Emerging Market, and biosimilar portfolios while maintaining focus on cost optimization and R&D innovation.

Q2 FY26 results highlighted superior operating leverage driven by strong performance in key export markets and disciplined expense control.

Financial Highlights (Q2 FY26)

Metric	Q2 FY26	YoY	QoQ
Revenue	₹5,670 Cr	+8%	+4%
EBITDA	₹1,720 Cr	+22%	+10%
EBITDA Margin	30.3%	+359 bps	+180 bps
PAT	₹1,010 Cr	+30%	+12%

Revenue ₹5,670 Cr — led by US generics and Emerging-Market growth.

EBITDA ₹1,720 Cr — margin expansion aided by higher realisations and cost control.

PAT ₹1,010 Cr — reflects operating strength and favourable product mix.

Traders tracking pharma momentum may follow Nifty Scalping Tip.

Peer Comparison

Company	EBITDA Margin	Focus Area
Lupin	30.3%	US & EM Generics
Dr Reddy’s	26%	Global Generics
Sun Pharma	29%	Specialty & Domestic

Strengths & Weaknesses

Strengths ✅ Strong US pipeline & biosimilar launches. ✅ Cost efficiency & stable gross margins.

Weaknesses ⚠️ Litigation risk in US market. ⚠️ R&D spend pressure (~7.5% of sales).

Opportunities & Threats

💡 Biosimilar approvals in EU & US. 💡 Expansion in tolvaptan and mirabegron markets.

📉 Pricing pressure in US generics. 📉 Regulatory delays at Nagpur plant.

Valuation & Investment View

• Short-term: Positive bias on strong Q3 visibility.
• Medium-term: Focus on US launches and biosimilars to sustain growth.
• Long-term: Margin expansion likely with R&D efficiency gains.

Monitor setups using BankNifty Scalping Tip.

Investor Takeaway

Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, notes that Lupin’s consistent US growth and improving product mix make it a solid mid-cap pharma pick. Explore more insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.

SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions.

Lupin Q2 FY26, Pharma Earnings, NUVAMA on Lupin, Indian-Share-Tips.com